# A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan

> **NCT06925113** · — · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 509 (actual)

## Conditions studied

- Cervical Cancers
- Endometrial Cancer
- Ovarian Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06925113
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-31
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-09-26
- **Target enrollment:** 509 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06925113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06925113, "A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06925113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*